These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282 [TBL] [Abstract][Full Text] [Related]
31. Clinical uses of anti-thymocyte globulin (ATGAM), Part I. Gilbert C N C Med J; 1984 Nov; 45(11):737-9. PubMed ID: 6392893 [No Abstract] [Full Text] [Related]
32. Use of rabbit ATG in cadaver kidney transplantation: an updated report with consideration of presensitized recipients. Davis RC; Nabseth DC; Olsson CA; Idelson BA; Schmitt GW; Cho SI; Mannick JA Transplant Proc; 1974 Dec; 6(4 Suppl 1):67-70. PubMed ID: 4612906 [No Abstract] [Full Text] [Related]
33. Clinical significance of T cell monitoring during antithymocyte globulin induction in renal transplantation. Thervet E; Chatenoud L; Legendre C; Mamzer-Bruneel MF; Kreis H; Bach JF Transplant Proc; 1997 Aug; 29(5):2330-1. PubMed ID: 9270748 [No Abstract] [Full Text] [Related]
34. Antirejection treatment with anti-thymocyte globulin in renal transplant recipients treated with cyclosporine as basic immunosuppression. Hoitsma AJ; Wetzels JF; Berden JH; Koene RA Transplant Proc; 1988 Oct; 20(5 Suppl 6):12-3. PubMed ID: 3051578 [No Abstract] [Full Text] [Related]
35. The high dose therapy of anti-human lymphoblast globulin in living related renal transplantation. Dohi K; Fukuda Y; Asahara T; Yahata H; Ono E; Takenaka M; Marubayashi S; Omotehara T; Tabe Y; Eto T Hiroshima J Med Sci; 1984 Jun; 33(2):223-31. PubMed ID: 6384144 [No Abstract] [Full Text] [Related]
36. Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation. Taylor HE; Ackman CF; Horowitz I Can Med Assoc J; 1976 Dec; 115(12):1205-8. PubMed ID: 793705 [TBL] [Abstract][Full Text] [Related]
37. Monitoring and modulation of immune reactivity in human transplant recipients. Thomas F; Lee HM; Wolf JS; Mendez-Picon G; Thomas J Surgery; 1976 Apr; 79(4):408-13. PubMed ID: 769221 [TBL] [Abstract][Full Text] [Related]
38. Development of a tolerogenic immune balance and elimination of autoreactive B cells--two important effects of antithymocyte globulin treatment. Söderström T; Olausson M; Blohmé I; Enskog A; Mjörnstedt L; Wramner L; Kjellson B; Brynger H Transplant Proc; 1990 Aug; 22(4):1795-7. PubMed ID: 2117810 [No Abstract] [Full Text] [Related]
39. Antithymocyte globulin as the primary treatment for renal allograft rejection. Nelson PW; Cosimi AB; Delmonico FL; Rubin RH; Tolkoff-Rubin NE; Fang L; Russell PS Transplantation; 1983 Nov; 36(5):587-9. PubMed ID: 6356523 [No Abstract] [Full Text] [Related]
40. Effects of different ATG (ATGAM) regimens on levels of rosette-forming cells (RFC), serum horse IgG (HoI), and anti-horse antibodies in kidney transplant patients. Satoh P; Elberg A; Davis J; Uittenbogaart C; Fine R; Hardy MA Transplant Proc; 1979 Jun; 11(2):1427-8. PubMed ID: 382530 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]